Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 3 Interventional Results available

A Randomized Controlled Trial of Aliskiren in the Prevention of Major Cardiovascular Events in Elderly People

ClinicalTrials.gov ID: NCT01259297

Public ClinicalTrials.gov record NCT01259297. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 16, 2026, 7:28 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Study identification

NCT ID
NCT01259297
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 3
Lead sponsor
Novartis Pharmaceuticals
Industry
Enrollment
2,336 participants

Conditions and interventions

Interventions

  • Aliskiren Drug
  • Amlodipine Drug
  • Hydrochlorothiazide (HCTZ) Drug
  • Placebo for Aliskiren Drug
  • Placebo for Amlodipine Drug
  • Placebo for Hydrochlorothiazide (HCTZ) Drug

Drug

Eligibility (public fields only)

Age range
65 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 31, 2010
Primary completion
Oct 31, 2012
Completion
Oct 31, 2012
Last update posted
Apr 7, 2014

2011 – 2012

United States locations

U.S. sites
14
U.S. states
11
U.S. cities
14
Facility City State ZIP Site status
Novartis Investigative Site Birmingham Alabama 35205
Novartis Investigative Site Los Angeles California 90033
Novartis Investigative Site Northridge California 91325
Novartis Investigative Site Sylmar California 91342
Novartis Investigative Site Tucker Georgia 30084
Novartis Investigative Site Pocatello Idaho 83209
Novartis Investigative Site Haverhill Massachusetts 01830
Novartis Investigative Site St Louis Missouri 63125-4181
Novartis Investigative Site Westfiled New York 14787
Novartis Investigative Site Winston-Salem North Carolina 27157
Novartis Investigative Site Portland Oregon 97239
Novartis Investigative Site Falls Church Virginia 22042
Novartis Investigative Site Marshfield Wisconsin 54449
Novartis Investigative Site Milwaukee Wisconsin 53295

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 171 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01259297, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 7, 2014 · Synced May 16, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01259297 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →